Novartis ($NVS) was last year's biggest R&D spender in the pharma industry. Now, the company is warning U.K. officials that, unless they change their ways, Novartis will be spending less and less of its research billions in that country. Report
The biopharm sales rep detailing physicians in New York faces a different environment from his colleagues in London or Tokyo. Cost-effectively designing a coordinated training program for these reps can be very difficult. This paper outlines ways to make the design process more efficient and effective. Download today.
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 100,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!